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Abstract
Background: Most test systems for acetylcholinesterase activity (E.C.3.1.1.7.) are using toxic
inhibitors (BW284c51 and iso-OMPA) to distinguish the enzyme from butyrylcholinesterase
(E.C.3.1.1.8.) which occurs simultaneously in the cerebrospinal fluid. Applying Ellman's colorimetric
method, we were looking for a non-toxic inhibitor to restrain butyrylcholinesterase activity. Based
on results of previous in vitro studies bupivacaine emerged to be a suitable inhibitor.
Results:  Pharmacokinetic investigations with purified cholinesterases have shown maximum
inhibition of butyrylcholinesterase activity and minimal interference with acetylcholinesterase
activity at bupivacaine final concentrations between 0.1 and 0.5 mmol/l. Based on detailed analysis
of pharmacokinetic data we developed three equations representing enzyme inhibition at
bupivacaine concentrations of 0.1, 0.2 and 0.5 mmol/l. These equations allow us to calculate the
acetylcholinesterase activity in solutions containing both cholinesterases utilizing the extinction
differences measured spectrophotometrically in samples with and without bupivacaine. The
accuracy of the bupivacaine-inhibition test could be confirmed by investigations on solutions of
both purified cholinesterases and on samples of human cerebrospinal fluid. If butyrylcholinesterase
activity has to be assessed simultaneously an independent test using butyrylthiocholine iodide as
substrate (final concentration 5 mmol/l) has to be conducted.
Conclusions: The bupivacaine-inhibition test is a reliable method using spectrophotometrical
techniques to measure acetylcholinesterase activity in cerebrospinal fluid. It avoids the use of toxic
inhibitors for differentiation of acetylcholinesterase from butyrylcholinesterase in fluids containing
both enzymes. Our investigations suggest that bupivacaine concentrations of 0.1, 0.2 or 0.5 mmol/
l can be applied with the same effect using 1 mmol/l acetylthiocholine iodide as substrate.
Background
AChE activity (E.C.3.1.1.7.) in CSF is assayed to study the
function of cholinesterase releasing cells in the nervous
system [1–8]. AChE and BChE (E.C.3.1.1.8.) are ob-
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served simultaneously in the CSF. Various methods to
measure the enzymatic activity of AChE in CSF have
been employed [9–16]. AChE hydrolyses only acetylcho-
line whereas BChE metabolizes acetylcholine as well as
butyrylcholine. Overlapping substrate specificity thereby
limits the use of colorimetric tests based on the assay re-
ported by Ellman et al. [17]. Therefore the majority of
colorimetric test procedures published to date are using
relatively specific (highly toxic) inhibitors to distinguish
the two different cholinesterases in the test system. We
introduced an inhibitor-free test for AChE and BChE in
the CSF [18]. During our recent studies we performed in
vitro inhibition tests on AChE and BChE using various
pharmacological agents [8]. We observed that a number
of these pharmaceuticals can affect the test system by in-
hibiting the activity of cholinesterases. Interestingly
pharmacokinetics of some drug-enzyme interactions
were relatively specific suggesting bupivacaine to be a
suitable agent for in vitro differentiation of cholineste-
rases.
The aim of this study was to develop an AChE assay for
CSF using bupivacaine to inhibit BChE activity.
We performed in vitro tests using purified cholinesteras-
es to define the bupivacaine concentration achieving
maximum inhibition of BChE activity and at the same
time influence AChE activity only to a minor degree.
Based on pharmacokinetic analysis we developed equa-
tions, which allow us to calculate the AChE activity in so-
lutions of both cholinesterases using the extinction
differences measured spectrophotometrically in samples
with and without bupivacaine. To confirm the correct-
ness of these equations we applied the newly developed
method to solutions of purified AChE and BChE as well
as to samples of human lumbar CSF. The bupivacaine-
inhibition test was also compared to the inhibitor-free
test.
Results
AChE hydrolyses ACh with maximum activity at a final
substrate concentration of 1 mmol/l. This substrate con-
centration was therefore used for all investigations.
BChE shows only one quarter of its maximum activity at
ACh final concentration of 1 mmol/l (Figure 1).
The influence of bupivacaine on the activity of both
cholinesterases is demonstrated in Figure 2. AChE activ-
ity and BChE activity were determined in separate anal-
yses. BChE inhibition above 95% of its activity was not
achieved even at bupivacaine concentration of 1 mmol/l.
The remaining BChE activity of 5% must therefore be
added to all BChE activities measured under the influ-
ence of bupivacaine. Using drug concentrations which
have minimum influence on AChE activity but cause
maximum inhibition of BChE we selected three bupi-
vacaine concentrations (0.1; 0.2 and 0.5 mmol/l) for fur-
ther investigation (Figure 3).
99% of AChE- and 20% of BChE activity were detected
(15% BChE activity measured plus 5% activity always re-
maining at higher bupivacaine concentration) following
application of 0.1 mmol/l bupivacaine to the test system.
Using 0.2 mmol/l bupivacaine 97% of AChE- and 15% of
BChE activity persisted (10% BChE activity measured
plus 5% activity always remaining). With 0.5 mmol/l
bupivacaine 93% of AChE- and 10% of BChE activity per-
sisted (5% BChE activity measured plus 5%).
Based on these findings the following equations for cal-
culation of extinction differences (∆ Einhibited) at bupi-
vacaine concentrations tested (0.1; 0.2 and 0.5 mmol/l)
were created:
(1a) ∆ Einhibited
0.1 = 0.99 ∆ EAChE + 0.20 ∆ EBChE
(2a) ∆ Einhibited
0.2 = 0.97 ∆ EAChE + 0.15 ∆ EBChE
(3a) ∆ Einhibited
0.5 = 0.93 ∆ EAChE + 0.10 ∆ EBChE
Equation for the total extinction difference without bupi-
vacaine inhibition (∆ Etotal):
(4a) ∆ Etotal = 1.00 ∆ EAChE + 1.00 ∆ EBChE
Extracting ∆ EAChE:
(4b) ∆ EAChE = ∆ Etotal - 1.00 ∆ EBChE
(1b) ∆ EAChE = 1.01 ∆ Einhibited
0.1 - 0.202 ∆ EBChE
(2b) ∆ EAChE = 1.03 ∆ Einhibited
0.2 - 0.155 ∆ EBChE
(3b) ∆ EAChE = 1.055 ∆ Einhibited
0.5 - 0.108 ∆ EBChE
Introduction of equation (4b) into equations (1b) – (3b):
(1c) 0.798 ∆ EBChE = ∆ Etotal - 1.01 ∆ Einhibited
0.1
(2c) 0.845 ∆ EBChE = ∆ Etotal - 1.03 ∆ Einhibited
0.2
(3c) 0.892 ∆ EBChE = ∆ Etotal - 1.055 ∆ Einhibited
0.5
Extraction of ∆ EBChE:
(1d) ∆ EBChE = 1.253 ∆ Etotal - 1.266 ∆ Einhibited
0.1
(2d) ∆ EBChE = 1.183 ∆ Etotal - 1.219 ∆ Einhibited
0.2
(3d) ∆ EBChE = 1.120 ∆ Etotal - 1.182 ∆ Einhibited
0.5BMC Biochemistry 2001, 2:17  http://www.biomedcentral.com/1471-2091/2/17
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Introduction of equations (1d) – (3d) into equation (4b):
(1e)  ∆ EAChE = ∆ Etotal - (1.253 ∆ Etotal - 1.266
∆ Einhibited
0.1)
(2e)  ∆ EAChE = ∆ Etotal - (1.183 ∆ Etotal - 1.219
∆ Einhibited
0.2)
(3e)  ∆ EAChE = ∆ Etotal - (1.120 ∆ Etotal - 1.182
∆ Einhibited
0.5)
Final equations to calculate ∆ EAChE:
(1f) ∆ EAChE = 1.266 ∆ Einhibited
0.1 - 0.253 ∆ Etotal
(2f) ∆ EAChE = 1.219 ∆ Einhibited
0.2 - 0.183 ∆ Etotal
(3f) ∆ EAChE = 1.182 ∆ Einhibited
0.5 - 0.120 ∆ Etotal
As mentioned under methods ∆ EAChE must be multi-
plied with factor 65 to calculate the AChE activity:
(1) AChE (nmol/min ×  ml) = 82.290 ∆ Einhibited
0.1 -
16.445 ∆ Etotal
(2) AChE (nmol/min ×  ml) = 79.235 ∆ Einhibited
0.2 -
11.895 ∆ Etotal
(3) AChE (nmol/min ×  ml) = 76.83 ∆ Einhibited
0.5 - 7.800
∆ Etotal
Purified enzymes
To prove the practical relevance of equations (1) – (3) we
performed the following laboratory investigations. Sam-
Figure 1
Activity of purified AChE and BChE (in %) in relation to substrate concentration. AChE hydrolyses ACh only; BChE reacts with
ACh and BCh.BMC Biochemistry 2001, 2:17  http://www.biomedcentral.com/1471-2091/2/17
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ples of purified AChE and BChE were mixed in Ringer
solution. We then measured the AChE activity using the
bupivacaine-inhibition test and compared these results
to the known enzyme activity in the solution. Using 0.1
mmol/l bupivacaine for inhibition of BChE we detected
99.2 ± 0.8% (94.7–103.3%) of the AChE activity original-
ly set up in the mixture of both cholinesterases. The re-
covery rate for the AChE activity using 0.2 mmol/l
bupivacaine was 99.7 ± 0.8% (94.0–105.0%). With 0.5
mmol/l bupivacaine we detected 98.2 ± 1.0% (94.7–
100.4 %) of the original AChE activity. Detailed results
are given in Table 1. The mean AChE activity detected
with the bupivacaine-inhibition test (either bupivacaine
concentration tested) did not differ significantly (Mann-
Whitney-Test: p > 0.05) from the original enzyme activ-
ity in the solution with BChE.
We did not find significant differences between test re-
sults obtained with different bupivacaine concentrations
(0.1; 0.2 and 0.5 mmol/l) comparing the mean recovery
rates for AChE (Mann-Whitney-Test: p > 0.05).
CSF
Investigations were performed to check the suitability of
the bupivacaine-inhibition test for lumbar CSF samples
as source of cholinesterases. Comparison of mean recov-
ery rates for AChE activity obtained using different bupi-
vacaine concentrations (0.1; 0.2 and 0.5 mmol/l) did not
show any significant differences between sample groups
(Mann-Whitney-Test: p > 0.05).
We compared the AChE activity obtained with the bupi-
vacaine-inhibition test to results acquired with the si-
multaneously conducted inhibitor-free test. AChE
activity of CSF samples investigated varied from 8 to 35
nmol/ min ×  ml. Exact data can be obtained from Table
2.
On average the mean AChE activity measured with the
inhibitor-free test was 3% lower than the activity meas-
ured using the bupivacaine-inhibition test (Wilcoxon-
Test: p < 0.05). This difference was seen with all three
bupivacaine concentrations used. To confirm this find-
Figure 2
Activity of purified AChE and BChE (in %; hairline at 5% and 100%) in relation to bupivacaine concentration (0–10-3 mol/l).BMC Biochemistry 2001, 2:17  http://www.biomedcentral.com/1471-2091/2/17
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ing we calculated 103% of each individual test result ob-
tained with the inhibitor-free method and compared
these computed data to the bupivacaine-inhibition test
results (Table 2). We could thereby eliminate significant
differences between the mean AChE activity obtained by
the two methods (Wilcoxon-Test: p > 0.05).
Discussion
The assay described in this paper is an elegant method to
distinguish AChE- from BChE activity in body fluids con-
taining both cholinesterases. This was achieved by using
bupivacaine as a save alternative to the BChE inhibitor
iso-OMPA [13,16]. Bupivacaine proved to be a relatively
selective BChE inhibitor in final concentrations from 1.0
to 5.0 ×  10-4 mol/1, AChE inhibition remaining below
10%. Three equations (0.1; 0.2 and 0.5 mmol/l bupi-
vacaine concentration) were generated after analysis of
pharmacokinetic data (Figure 1).
The accuracy of equations (1) – (3) was first confirmed by
a test series detecting the AChE activity in solutions of
purified AChE and BChE. Alltogether 99.3 ± 0.5 % of the
AChE activity originally set up in test solutions were de-
tected. There were no significant differences comparing
the mean AChE recovery rates obtained with 0.1 mmol/
l; 0.2 mmol/l or 0.5 mmol/l bupivacaine.
Furthermore the relevance of the bupivacaine-inhibition
test was confirmed by analysis of human CSF samples.
Comparison of the mean AChE recovery rates did not re-
veal significant differences between test results acquired
with either 0.1 mmol/l; 0.2 mmol/l or 0.5 mmol/l bupi-
Figure 3
Activity of purified AChE and BChE (in %; hairline at 5% and 100%) in relation to bupivacaine concentration (1.0–5.0 ×  10-4
mol/l).BMC Biochemistry 2001, 2:17  http://www.biomedcentral.com/1471-2091/2/17
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vacaine. All three drug concentrations can therefore be
applied equally with the bupivacaine-inhibition test.
Until recently we have been using the inhibitor-free test,
which permits for simultaneous analysis of both
cholinesterases in the CSF [18]. The inhibitor-free meth-
od is based on the finding that the ratio of individual ac-
tivities of BChE on its both substrates ACh and BCh in
the CSF and in the serum obtained at the same time are
identical with substrate concentrations of at least 5
mmol/l. It became obvious that at 5 mmol/l ACh concen-
tration the AChE activity already shows moderate inhibi-
tion by its substrate (Figure 1). This substrate inhibition
evidently causes about 3% lower enzyme activity meas-
ured with the inhibitor-free test in comparison to the
bupivacaine-inhibition test (Table 2). However, the
AChE activity was not inhibited by ACh at 1 mmol/l sub-
strate concentration (Figure 1) which is used for the
bupivacaine-inhibition test. We were able to show that
significant mean AChE activity differences between the
two test procedures could be eliminated adding 3% of the
enzyme activity measured with the inhibitor-free proce-
dure to the original data obtained by this method (Table
2).
It does not appear advisable to judge whether the bupi-
vacaine-inhibition test or the inhibitor-free test is more
precise when one considers the minor differences be-
tween test results. We could previously show that the in-
hibitor-free procedure offers widely identical results in
comparison to the difference method using BW284c51 as
AChE-inhibitor which proved to be a trustworthy assay
[9,11,12,15,18]. We could also show that the assay utiliz-
ing iso-OMPA as inhibitor for BChE exclusively [14] is
unreliable if applied without correction of methodical er-
rors [18]. So far no substance has been found which com-
pletely inhibits BChE without also affecting AChE.
Bupivacaine is no exception. It is thus obvious that any
Table 1: AChE activity recovered from mixture of purified AChE and BChE using the bupivacaine-inhibition test
bupivacaine concentration n original AChE activity recovered AChE activity using
(mmol/l) nmol/min (± SEM) bupivacaine-inhibition test
nmol/min ×  ml (± SEM)
0.1 14 43.5 ± 1.5 (35.8–56.5) 43.2 ± 1.5 (34.4–56.0)
0.2 17 49.7 ± 2.7 (25.6–64.5) 49.5 ± 2.6 (26.5–64.2)
0.5 6 51.2 ± 6.2 (29.7–71.2) 50.2 ± 6.0 (29.8–69.8)
Table 2: Mean AChE activity ± SEM (nmol/min ×  ml) in lumbar CSF samples measured with the bupivacaine-inhibition test and the in-
hibitor-free test.
bupivacaine 
concentration 
(mmol/l)
n AChE activity
bupivacaine-inhibi-
tion test
inhibitor-free test calculated data: inhibitor-free 
test result +3%
nmol/min ×  ml ± SEM 
(range)
% measured nmol/min ×  ml ± SEM 
(range)
% defined nmol/min ×  ml ± SEM %
0.1 45 21.6 ± 0.1 (8.7–34.3) 102.8 ± 0.6 20.9 ± 0.0 (9.0–32.8) 100 21.6 ± 1.0 (9.3–33.8) 103
0.2 45 21.5 ± 0.1 (8.6–34.7) 102.4 ± 0.6 20.9 ± 0.0 (9.0–32.8) 100 21.6 ± 1.0 (9.3–33.8) 103
0.5 8 16.6 ± 1.0 (12.6–19.6) 103.4 ± 1.2 16.1 ± 1.0 (12.5–19.6) 100 16.6 ± 1.1 (12.7–20.2) 103
The mean AChE activity measured with the inhibitor-free test was defined as 100% activity. 3% of each individual test result obtained with the inhib-
itor-free method were added to the original data and the calculated mean AChE activity ± SEM (103%) was displayed.BMC Biochemistry 2001, 2:17  http://www.biomedcentral.com/1471-2091/2/17
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procedure computing the AChE activity after inhibition
of either cholinesterase has its disadvantages. However
incomplete inhibition of BChE and additional AChE in-
hibition can be handled by studying pharmacokinetics
(known enzyme activity and inhibitor concentration) to
precisely determine the impact of these unwanted ef-
fects.
The inhibitor-free test and the bupivacaine-inhibition
test are both accurate assays to measure the AChE activ-
ity in CSF. The inhibitor-free procedure requires an ad-
ditional serum sample to be taken at the same time as the
CSF sample and is therefore a little more expensive than
the bupivacaine-inhibition test. Still the inhibitor-free
test should be the method of choice if both cholinesteras-
es in the CSF and the BChE activity in the serum have to
be assessed simultaneously. If only the AChE activity has
to be assayed the bupivacaine-inhibition test ought to be
used because it is cheaper and easy to perform. Bupi-
vacaine is a save inhibitor and could even be provided to-
gether with the substrate ACh, DTNB and eserine
salizylate in a standardized test kit.
BChE activity in serum or CSF can of course be tested in-
dependently employing the substrate butyrylthiocholine
iodide at a final concentration of 5 mmol/l. BChE shows
its full activity only at this substrate concentration (Fig-
ure 1), AChE being unable to compromise the test result
because of its substrate specificity.
Conclusions
The bupivacaine-inhibition test is a reliable method to
measure AChE activity in CSF. It avoids the use of toxic
inhibitors to differentiate AChE- from BChE activity in
fluids containing both enzymes. Our investigations sug-
gest that bupivacaine concentrations of 0.1, 0.2 or 0.5
mmol/l can be applied equally using the substrate
acetylthiocholine iodide at a final test concentration of 1
mmol/l.
Material and Methods
Purified AChE (cholinesterase, acetyl C 2888 Type V-S:
from electric eel; 1000–2000 U/mg) and purified BChE
(cholinesterase, butyryl C 4290 from horse serum, highly
purified minimum 500 U/mg) were obtained from Sig-
ma-Aldrich Co. Acetylthiocholine iodide >/= 99% (AT),
butyrylthiocholine iodide ~99% (AT), 5-5'dithio bis-(2-
nitrobenzoic acid) (3,3'-6) ~99% (HPLC) and eserine sal-
izylate were obtained from Fluka BioChemika. Bupi-
vacaine-hydrochloride (Carbostesin® 0.25%) was
obtained from Astra GmbH Wedel, Germany.
Enzyme assay
AChE- and BChE activity were measured spectrophoto-
metrically applying the technique of Ellman et al. [17].
Samples containing purified AChE and BChE dissolved
in Ringer (0.1 ml solution) and samples of human lum-
bar CSF (0.1 ml; cell-free) were investigated. The sub-
strate ACh was used at a final concentration of 1 mmol/l.
The final concentration of DTNB was 1 mmol/l. The re-
action was performed at 37°C in a total volume of 1.3 ml
and stopped after 20 min linear reaction time using 0.5
ml of 0.1 mmol/l eserine salizylate. The reaction product
5-thio-2-nitrobenzoate produced enzymatically was
measured at 412 nm. AChE activity was calculated by
multiplication of the extinction difference (∆ EAChE)
with factor 65 which results from the volume of the reac-
tants, the total volume of 1.8 ml the reaction time of 20
min and the millimolar extinction coefficient of 13.88.
The inhibitor-free test was described in detail in one of
our previous publications [18].
Tests using purified enzymes
Test-series were performed on samples containing puri-
fied AChE and BChE. The inhibition effect of three differ-
ent bupivacaine concentrations (0.1; 0.2 and 0.3 mmol/
l) was investigated:
60 samples (mean AChE activity: 43.5 ± 1.3 nmol/ min ×
ml; 35.8 – 56.5 nmol/ min ×  ml) were tested under the
influence of 0.1 mmol/l bupivacaine.
85 samples (mean AChE activity: 49.8 ± 2.7 nmol/ min ×
ml; 25.6 – 64.5 nmol/ min ×  ml) were investigated using
0.2 mmol/l bupivacaine.
24 samples (mean AChE activity: 51.2 ± 6.2 nmol/ min ×
ml; 29.7 – 71.2 nmol/ min ×  ml) and BChE were tested
with 0.5 mmol/l bupivacaine.
Tests using human CSF
Investigations were performed to check the applicability
of the bupivacaine-inhibition test for human lumbar
CSF. Samples remaining after completed routine labora-
tory analysis were used. We compared the mean recovery
rates for AChE activity obtained under the influence of
different bupivacaine concentrations (0.1; 0.2 and 0.5
mmol/l). Lumbar CSF samples were also used to com-
pare the bupivacaine-inhibition test with the inhibitor-
free test. Three test-series were performed. 45 CSF sam-
ples were examined applying 0.1 mmol/l bupivacaine
and 0.2 mmol/l bupivacaine respectively. 8 CSF samples
were assayed under the influence of 0.5 mmol/l bupi-
vacaine.
Statistical tests
Data are given as means ± SEM. We used nonparametric
tests to compare means of sample groups (Mann-Whit-
ney-Test for independent sample groups and Wilcoxon-BMC Biochemistry 2001, 2:17  http://www.biomedcentral.com/1471-2091/2/17
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Test for dependent sample groups). The level of signifi-
cance was set at 0.05. Tests were performed using SPSS
9.0 for Windows®.
Abbreviations
BW284c51: 1,5-bis(4-allyldimethylammoniumphenyl)-
pentan-3-one dibromide
∆ E: extinction difference
∆ Einhibited: extinction difference measured under the in-
fluence of bupivacaine
∆ Etotal: extinction difference measured without bupi-
vacaine
ACh: acetylthiocholine iodide
AChE: acetylcholinesterase
BCh: butyrylthiocholine iodide
BChE: butyrylcholinesterase
CSF: cerebrospinal fluid
DTNB: 5-5'dithio bis-(2-nitrobenzoic acid) (3,3'-6)
iso-OMPA: tetraisopropylpyrophosphoramide
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